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Total-liver-volume perfusion CT using 3-D
image fusion to improve detection
and characterization of liver metastases
Abstract The purpose of this study
was to evaluate the feasibility of a total-
liver-volume perfusion CT (CTP)
technique for the detection and char-
acterization of liver metastases. Twenty
patients underwent helical CT of the
total liver volume before and 11 times
after intravenous contrast-material
injection. To decrease distortion arti-
facts, all phases were co-registered
using 3-D image fusion before creating
blood-flow maps. Lesion-based sensi-
tivity and specificity for liver metas-
tases of first the conventional four
phases (unenhanced, arterial, portal
venous, and equilibrium) and later all
12 phases including blood-flow maps
were determined as compared to intra-
operative ultrasound and surgical ex-
ploration. Arterial and portal venous
perfusion was calculated for normal-
appearing and metastatic liver tissue.
Total-liver-volume perfusion values
were comparable to studies using
single-level CTP. Compared to four-
phase CT, total -liver-volume CTP
increased sensitivity to 89.2 from
78.4% (P=0.046) and specificity to
82.6 from 78.3% (P=0.074). Total -
liver-volume CTP is a noninvasive,
quantitative, and feasible technique.
Preliminary results suggest an im-
proved detection of liver metastases for
CTP compared to four-phase CT.
Keywords Perfusion . Computed
tomography (CT) . Liver metastasis
Introduction
Until recently the only potentially curative strategy for
patients with colorectal liver metastases was surgical
resection. During the last few years, several alternative
local ablative therapies, such as radiofrequency ablation,
have also been suggested to improve survival [1, 2]. The
results of these local forms of therapy strongly depend on
the accuracy of pre- and intraoperative imaging. Any
technique that increases sensitivity and specificity for the
detection of liver metastases and that improves the
evaluation of local tumor extent will therefore probably
not only improve survival but may also prevent patients
from receiving unnecessary invasive forms of surgery.
In the preoperative assessment of liver tumors, single-
phase computed tomography (CT) is often insufficient to
characterize focal liver lesions due to the variable en-
hancement patterns of liver tumors compared to the
relatively constant enhancement pattern of normal liver
parenchyma. Moreover single-phase CT is inferior to
multiphase CT in the detection of focal liver lesions [3–5].
Therefore, multiphase CT has been widely accepted as the
imaging modality of first choice either for the workup of
focal liver lesions or as the primary imaging modality when
suspicion of liver malignancy is high. Adding more phases
may further improve detection and characterization of focal
liver lesions.
Since the early 1990s, a single-level, dynamic, contrast-
enhanced perfusion CT (CTP) technique that allows for the
quantification and mapping of hepatic tumor blood-flow
parameters such as tissue perfusion has been examined
by a relatively small group of investigators [6–19]. CT
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measurements of hepatic perfusion amongst patients with
colon cancer have been shown to correlate with patient
survival in two small groups of patients [10, 11] and to
provide risk stratification possibly even superior to the
Dukes’ classification [18, 19]. Furthermore, the presence
of a focal arterial hyperdense blush and a general
increase in global hepatic artery tissue perfusion on CTP
may indicate the presence of occult micrometastasis [8,
9]. CTP has also been successful in demonstrating a
significant decrease of 40–44% in tumor blood perfusion
after antiangiogenic therapy, and therefore CTP may
serve as a biomarker for tumor response [20].
Two major limitations, however, have hampered the use
of CTP. Because of the necessity of a high temporal
resolution to produce reliable enhancement curves for
every voxel within a certain volume, older CT machines
were simply not fast enough to acquire repeated examina-
tions of the entire liver every few seconds. Secondly,
heterogeneity in either inspiratory or expiratory volumes
between two successive breathing in and out commands
have previously produced severe motion and distortion
artifacts of the liver and have so severely degraded the
quality of enhancement curves that reliable calculations of
perfusion parameters were impossible.
The purpose of this study was to evaluate the feasibility
of a total-liver-volume CTP technique for the detection and
characterization of liver metastases. The authors describe
their early experience with this ultrafast total-liver-volume
contrast-enhanced perfusion CT, in which an automated 3-
D image fusion technique was applied to decrease motion
and distortion artifacts induced by differences in inspira-
tory volume.
Materials and methods
Patient selection
Between July 2006 and March 2007, 20 consecutive
patients (14 male; 6 female) suitable for surgical resection
and/or radiofrequency ablation of liver metastases were
selected for this study. The mean age was 64 years (range,
48–80 years). Nineteen patients had liver metastases from
primary colorectal carcinoma, and one patient had liver
metastases from an adenocarcinoma of unknown primary
origin. Additional selection criteria were a WHO perfor-
mance status of 0–2 [21], a Karnofsky performance status
(KPS) ≥ 80%, a life expectancy of more than 3 months as
well as adequate hematological, renal and hepatic function,
measured as serum hemoglobin level, platelet and white
blood cell count, creatinin and bilirubin within the upper
limit of normal. Patients with known contrast-medium
reactions, patients unable to hold their breath for a
sufficient period of time, and patients unable to obey
breath-hold commands were excluded. The nutritional
status during CTexamination was normal in all patients (no
fasting period). All patients underwent CT no more than
24 h before surgery; the entire liver was examined by both
visual and palpatory inspection and intraoperative ultra-
sound (IOUS). The study was approved by the institutional
ethical and scientific review board, and all patients gave
written informed consent.
Imaging protocol
Dynamic CTP measurements were obtained with a 64-slice
multi-detector CT system (Somatom Sensation, Siemens,
Erlangen, Germany). A 12-phase helical CT examination
of the total liver volume (collimation 0.6 mm; rotation time
0.33 s; pitch 0.75) was acquired before and 11 times after
rapid intravenous injection (6 ml/s) of 100 ml low-osmolar
nonionic contrast agent with an iodine concentration of
300 mg/ml (Ultravist-300 Iopromide; Schering, Berlin,
Germany) and 20 ml saline chasing bolus into the left
antecubital vein, using an injection pump through an 18-g
needle.
Bolus tracking (threshold +100 HU) was used to start the
CT data acquisition, placing a region of interest (ROI) over
the right atrium. With a minimum interscan delay of 3–4 s
in between two series, the first four series were obtained in
one single breath-hold at maximum inspiration. After these
first series, one breath-out and breath-in command (lasting
8 s) was given before adding two series in one single
breath-hold at maximum inspiration. This was repeated
until a total of 11 series were acquired. The 10th series
(considered as the portal venous phase series) was obtained
during a single breath hold in which the entire (upper and
lower) abdomen was examined at conventional tube
voltage and current (120 kV and maximum 180 mAs
with dose modulation). In all other series, a fixed lower
tube current was used to reduce radiation exposure (120 kV
and 80 mAs). The 12th and final series was performed at
equilibrium after approximately 300 s. The timetable of
this protocol is displayed in Fig. 1. All series were
reconstructed in both 5-mm contiguous axial slices and thin
overlapping axial slices (slice width 1.5 mm; reconstruc-
tion increment 1.0 mm) for optimum visualization in the
multiplanar reconstruction mode of the 3-D fusion
program.
Radiation exposure
The effective dose, expressed according to the International
Commission on Radiological Protection recommendations
measured with commercially available software was
approximately 24.0 mSv (11×1.5 mSv + 1×7.5 mSv) for
the dynamic CTP protocol [22–24]. For comparison, using
the same scan range, the effective dose for only the
conventional four phases used in our protocol is approxi-
mately 12.0 mSv (3×1.5 mSv + 1×7.5 mSv). However, for
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a conventional-dose four-phase CT this would be approxi-
mately 20.7 mSv (3×4.4 mSv + 1×7.5 mSv).
Postprocessing
Initially the four-phase CT images [unenhanced and at 30 s
(5th or arterial phase), 70 s (10th or portal venous phase)
and 300 s (12th phase or equilibrium) after start of
injection] were extracted from the 12-phase CTP scan. An
experienced radiologist (J.H.v.W) unaware of the results of
the CTP evaluated the four phases and scored all visible
liver lesions as appearing either malignant or benign.
Image fusion was performed with a commercially
available 3-D image fusion program (Vinci 2.36.0, Max
Planck Institute for Neurological Research, Cologne). The
12 series were fused by a combination of automated and
manual image shifting using colored transparent image
overlay methods. The 10th (portal venous phase) series
was chosen as reference to which all other series were
registered in 5-mm contiguous axial slices. The time
necessary for the entire registration process of a single
examination was approximately 20–40 min. To assess the
effect of image fusion, time-density curves of subdia-
phragmatic regions of interest (ROIs), which are most
vulnerable to artifacts induced by differences in inspiratory
volume, were drawn on the most superior slice below the
diaphragm on the portal venous phase and subsequently
copied to all other phases before and after image registra-
tion (Fig. 2). Time-density curves were considered
Fig. 2 Graphs showing the time-density curves of ROIs placed in
the most superior slice below the diaphragm of the portal venous
reference phase, which is highly vulnerable to artefacts induced by
differences of inspiratory volume. The curves were subsequently
copied to all other phases, before (a, c) and after (b, d) 3-D image
fusion and co-registration. The improved shape of the time-
enhancement curves after image fusion will decrease distortion
artifacts on the blood-flow maps and lead to more reliable perfusion
values
Fig. 1 Timetable of the computed tomography perfusion protocol. All series were acquired during breath-hold at maximum inspiration, 1
series before and 11 series after the rapid administration of intravenous contrast material. The delay (d) between two acquisitions was 3 s
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unacceptable for calculation of perfusion and creation of
blood-flow maps if at least one time point had a density of
>10 HU below the precontrasted liver parenchyma or if a
decrease of >30 HU between two time points was present,
most likely representing the inclusion of lung parenchyma
or fatty extrahepatic tissue within the ROI.
For the quantification of tissue perfusion and for the
creation of blood-flow maps, the software program Basama
Perfusion 3.0.7.1 (Kanazawa, Ishikawa, Japan) was used
[16]. ROIs were placed within normal-appearing liver
parenchyma, within the hypodense lesions as determined
on the portal venous phase images and within a rim region
of approximately 1 cm surrounding these hypodense
lesions. The program estimates tissue perfusion as the
maximum slope of the tumor time-density curve divided by
the peak arterial enhancement. The mathematical technique
has previously been fully described elsewhere [6, 7, 25].
Due to the dual blood supply of the liver, hepatic tissue
perfusion is divided into hepatic artery and portal venous
perfusion as the maximum slope of the tumor time-density
curve before versus after the splenic peak enhancement
divided by, respectively, the peak aortic and portal
enhancement. For an example of the total volume CTP
blood-flow maps, see Fig. 3. The time necessary for
quantifying perfusion and creation of total-liver-volume
blood-flow maps of a single examination was approxi-
mately 20–40 min.
After at least 1 month to reduce recall bias, the same
experienced radiologist (J.H.v.W.) evaluated all 12 phases
including the hepatic artery and portal venous blood-flow
maps and again scored all visible lesions as appearing
either malignant or benign. Large lesions (>2 cm) were
considered to appear malignant on blood-flow maps if a
low central and high peripheral arterial perfusion was
found in combination with a low portal venous perfusion
compared to adjacent normal-appearing liver tissue. Small
lesions (<2 cm) were also considered to appear malignant if
the entire lesion presented with high arterial perfusion.
Previous porcine studies have shown that as cardiac
output decreases, the times to the arrival of the contrast-
medium bolus in the aorta and to peak aortic and hepatic
enhancement increase. Furthermore, reduction in cardiac
output results in a substantial increase in peak aortic
enhancement but not in peak hepatic enhancement [26].
Therefore, although somewhat arbitrary, to estimate the
influence of cardiac output on the perfusion parameters, we
used the time-to-peak and peak-enhancement values as
surrogate markers for cardiac output. Both arterial and
portal venous time-to-peak measurements and peak-
enhancement values were compared to the perfusion values.
Fig. 3 Total-volume CTP showing a selection of the portal venous phase images (a) and the hepatic artery (b) and portal vein (c) blood-
flow maps in a patient with multiple colorectal liver metastases
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Statistical analysis
To establish lesion-based sensitivity and specificity both
four-phase CT and CTP techniques were compared to a
gold standard of surgical exploration and IOUS. Pearson’s
product moment correlation coefficient was used to
determine the correlation between cardiac output estima-
tions and the perfusion values [correlation coefficients (r)
were considered as follows: <0.2 negligible, 0.2–0.4 weak,
0.4–0.7 moderate, 0.7–0.9 strong, and >0.9 very strong
correlation].
Results
In all patients, the CT protocol, the rapid injection of
contrast medium, and the breath-hold commands were well
tolerated. No patients had to be excluded.
Influence of image fusion
In 14/20 cases, before image fusion and registration, the
time-density curves of subdiaphragmatic ROIs were
considered unacceptable to calculate perfusion or to create
blood-flow maps due to the presence of lung parenchyma
or fatty extrahepatic tissue within the ROI at at least one
time point. After image fusion and registration all 20/20
time-density curves could be considered acceptable; no
lung parenchyma or fatty extrahepatic tissue was present
within the ROIs (Fig. 2).
Influence of cardiac output
The peak enhancement in the aorta on average was 368±
61 HU (range 259–471 HU) and the peak enhancement in
the portal vein was 188±32 HU (range 139–243 HU). The
average time-to-peak was 20.5±5.8 s (range 8–36 s) for the
aorta and 37.4±13.0 s (range 18–77 s) for the portal vein. A
shorter time-to-peak showed moderate to strong correlation
with higher peak enhancement (r=0.62 for the aorta and r=
0.71 for the portal vein). The aortic (r=0.39) and portal
vein (r=0.17) times-to-peak and the peak aortic (r=0.37)
and peak portal vein (r=0.36) enhancement all showed
weak or negligible correlations with perfusion values for
normal liver tissue, although a trend towards higher
perfusion in patients with higher peak enhancements and
lower time-to-peak values was present.
Evaluation of blood-flow maps
Almost all lesions were of considerably larger volume
when evaluated on the portal venous blood-flow maps
compared to the conventional portal venous phase images
before reconstruction. This volume mismatch resembles a
rim region that surrounds the hypodense and mainly
necrotic lesions visible on conventional CT, and that has a
very high hepatic artery flow (Fig. 4) of 32.1 ml min−1
100 g−1 on average. In calculating the portal venous
perfusion of the voxels within this region, the larger post-
peak dip of the hepatic artery perfusion curve superimposes
on the post-splenic-peak portal venous enhancement curve.
This may cause a decrease or even subzero post-splenic-
peak maximum slope, which would falsely lead to a
diminished or even negative portal venous flow. Portal
venous perfusion in these areas is therefore probably
underestimated and highly unreliable as has been pre-
viously described [20].
Detection and characterization of focal liver lesions
For the determination of sensitivity and specificity in the
detection of liver metastases, one patient had to be
excluded due to the preoperative presence of severely
progressive disease; more than 20 malignant-appearing
Fig. 4 Total-volume CTP showing the portal venous phase images
(a) and the hepatic artery (b) and portal venous (c) blood-flow maps
in a patient with a large colorectal liver metastasis. The mainly
necrotic metastasis (ROI1) is surrounded by a rim region with high
hepatic artery flow (ROI2) and bordered ventrally by a wedge-
shaped region with very high hepatic artery flow and absent or
immeasurable portal venous blood flow (ROI3)
2349
liver lesions were found (all visible on both the four-phase
CT images and the CTP images) making him unsuitable for
further surgical exploration and IOUS. In two other
patients, the only visible liver lesions appeared to be
benign, representing either simple cysts or hemangiomas.
Since in both cases, no surgical exploration or IOUS was
performed, the absence of PET avidity, the typical aspect
on targeted US examinations, and the absence of change or
growth after 3 months were used as alternative gold
standard. Based on the four-phase CT images alone a total
of 34 malignant-appearing lesions (29 true positives and 5
false positives: 3 simple hepatic cysts and 2 hemangiomas)
and 13 benign-appearing lesions were found (all true
negatives: 4 simple hepatic cysts, 1 hemangioma, 5 fully
cystic, well-margined post-RFA lesions, and 3 benign focal
perfusion alterations).
All 29 true-positive colorectal liver metastases (CRLM)
could be visualized on the portal venous phase images,
however the unenhanced and hepatic artery phase helped
characterize at least 5 small CRLM. To correctly diagnose
the hemangioma as a true benign “fill-in” lesion, the
equilibrium phase was indispensable. By adding the
additional CTP phases and the hepatic artery and portal
venous blood-flow maps to these conventional CT images,
a total of 37 malignant-appearing lesions (33 true positives
and 4 false positives: all 4 representing benign superficial
wedge-shaped focal perfusion alterations) and 16 benign-
appearing lesions were found (all true negatives: 7 simple
hepatic cysts, 3 hemangiomas, 5 post-RFA lesions, and 1
benign focal perfusion alteration). In the gold standard
group, a total of 37 liver metastases and 18 benign liver
lesions (7 simple hepatic cysts, 6 hemangiomas, and 5 post-
RFA lesions) were detected; 5 lesions detected on CTP
represented benign focal perfusion alterations. For a
summary of the results see Table 1.
Two examples of liver metastases undetected with four-
phase CT and detected with CTP are given in Fig. 5 and
Fig. 6. For the four-phase CT versus the CTP techniques,
we found a sensitivity of 78.4% versus 89.2% (P=0.046),
respectively, and a specificity of 78.3% versus 82.6%
(P=0.078). The positive predictive value of malignant-
appearing lesions was 85.3% versus 89.2% for four-phase
CT and CTP, respectively; the negative predictive value of
benign-appearing lesions was 100.0% for both four-phase
CT and CTP. Compared to the four-phase CT, four
additional liver metastases (in three patients) were detected
with CTP and eight (in four patients including the
previously mentioned three patients) with surgical explo-
ration and IOUS. The four additionally detected lesions
found with CTP all represented small lesions (<2.0 cm)
first visualized on the blood-flow maps, although retro-
spectively three out of four lesions were also vaguely
visible on one of the 12-phases. Histology confirmed the
metastatic nature in three of four additionally detected
CRLM. In the fourth additionally detected lesion no
histology was obtained due to progressions of disease
elsewhere in the liver (Fig. 5).
All liver metastases undetected with either four-phase
CT or CTP represented very small lesions (<1.0 cm). In
three out of four of these patients the treatment strategy
changed to no further local therapy, due to the technical
inability to resect and/or ablate all lesions. Since all four
falsely positive superficial wedge-shaped focal perfusion
alterations (in two patients) appeared small and technically
resectable on perfusion CT, retrospectively, the CTP results
would not have changed the decision to perform surgery.
Quantification
Average perfusion of the normal-appearing liver paren-
chyma was 18.7±7.1 ml min−1 100 g−1 for the hepatic
artery (range 8.5–33.2 ml min−1 100 g−1) and 57.2±20.6 ml
min−1 100 g−1 for the portal vein (range 23.3–108.3 ml
Table 1 Contingency tables with results for four-phase CT and CTP techniques
Malignant Benign Total
Four-phase CT compared to the gold standarda
Malignant-appearing lesions 29 (48%) 5 (8%) 34 (57%)
Benign-appearing lesions 0 (0%) 13 (22%) 13 (22%)
Lesions undetected with four-phase CT but detected with gold standard 8 (13%) 5 (8%) 13 (22%)
Total 37 (62%) 23 (38%) 60 (100%)
CTP compared to the gold standarda
Malignant-appearing lesions 33 (55%) 4 (7%) 37 62%)
Benign-appearing lesions 0 (0%) 16 (27%) 16 (27%)
Lesions undetected with CTP but detected with gold standard 4 (7%) 3 (5%) 7 (12%)
Total 37 (62%) 23 38%) 60 (100%)
aCombination of surgical exploration and IOUS (gold standard)
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min−1 100 g−1); hepatic artery contribution to the hepatic
blood flow (hepatic perfusion index or HPI) of normal-
appearing liver parenchyma was 26±11% (range 13–57%).
Average perfusion of the hypodense liver metastases was
8.2±5.3 ml min−1 100 g−1 for the hepatic artery (range 0–
16.9 ml min−1 100 g−1) and 17.0±16.5 ml min−1 100 g−1
for the portal vein (range 0–63.3 ml min−1 100 g−1); HPI
was 44±32% (range 0–100%). Average perfusion of the rim
regions surrounding these hypodense lesions was 32.1±
12.9 ml min−1 100 g−1 for the hepatic artery (range 12.6–
56.4 ml min−1 100 g−1) and 35.5±24.8 ml min−1 100 g−1
for the portal vein (range 0–89.4 ml min−1 100 g−1); HPI was
51±23% (range 23–100%).
Discussion
The preliminary results of this study suggest an improved
detection rate of colorectal liver metastases for the total-
volume CTP-based technique with 3-D image fusion. The
technique might also improve differentiation between
benign and malignant liver lesions, although distinction
between superficial wedge-shaped areas of nonmetastatic
altered liver tissue perfusion and the hyperdense blush
surrounding occult liver metastases seems impossible.
Therefore, the number of pre-procedurally detected liver
metastases may be somewhat overestimated compared to
four-phase CT. As a result, the mere presence of these
superficial wedge-shaped focal perfusion alterations on
CTP-derived blood-flow maps cannot exclude patients
from receiving surgery. For this reason the number of
patients in whom CTP will prevent unnecessary surgery
will probably be limited. Nevertheless, the presence of
these focal perfusion alterations can guide surgical
inspection and target IOUS to the presence of small and
previously occult liver metastases.
One important limitation of the study is the lower tube
current of 80 mAs used for the unenhanced, arterial, and
equilibrium phases to reduce radiation exposure. The most
important phase for detection of colorectal liver metastases,
namely the portal venous phase, was obtained with
conventional higher tube currents. Although in theory
these lower tube currents could have negatively influenced
the results of the four-phase CT, in all three patients where
additional liver metastases were found with CTP, a
conventional-dose four-phase CT had been performed no
more than 6 weeks before surgery. The conventional-dose
four-phase CT also did not reveal the lesions (both in the
radiology report and by retrospective blinded evaluation).
Both the ratio of hepatic artery over portal venous
perfusion and the arterial and portal venous perfusion
values of normal-appearing liver tissue are in accordance
with other studies using the direct maximum slope method,
where arterial versus portal venous perfusion ranged from
Fig. 5 Example of a small liver metastasis (white boxes) undetected
with four-phase CT [unenhanced (a); arterial phase (b); portal
venous phase (c)] and detected on the CTP blood-flow maps [arterial
(d) and portal vein (e)]. Surgical inspection and palpation of the
local liver surface and IOUS (f) clearly confirmed the metastatic
nature of the lesion, although no histology was obtained due to the
progression of disease elsewhere in the liver
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17 to 30 ml min−1 100 g−1 versus 34 to 106 ml min−1 100 g−1
[7, 8, 15, 17, 27].
The higher ratio of hepatic artery over portal venous
flow in the center of malignant lesions as well as in rim
regions surrounding nearly all colorectal liver metastases is
fully comparable to results from other studies. The
hypothetical mechanisms that lead to these observations
are difficult and most likely heterogeneous and multifac-
torial. First, for reasons that are not presently understood,
the proliferation of blood vessels that are dependent on
vascular endothelial growth factor in colorectal liver
metastases (angiogenesis) favors the recruitment of hepatic
artery branches over portal veins [28]. These blood-flow
alterations may be paralleled within a certain region
surrounding the tumor due to the local spread of tumoral
cytokines. Secondly, mechanical tumor compression and/
or peritumoral vessel lumen-narrowing secondary to fixed
leukocyte adherence will result in reduced portal flow [29].
Although under debate, decreased portal supply in the
compressed hepatic parenchyma has been suggested to
evoke a compensatory increase in arterial blood supply
[30]. Hepatic artery perfusion in these areas is probably
overestimated due to the decreased dilution within the
hepatic sinusoids of the highly dense contrasted arterial
blood with the not-yet-contrasted portal venous blood. The
combination of an increased arterial blood supply and
compression of hepatic veins might even produce local
reversion of flow resulting in draining portal veins [10].
Thirdly and fourthly, rim enhancement has been described
to be caused by the drainage of blood flow from the tumor
to the surrounding hepatic parenchyma in hypervascular
metastases or by increased arterioportal shunts surrounding
the tumor in hypovascular metastases [31]. Finally, peri-
lesional enhancement has been reported to correlate with
histopathologic hepatic parenchymal changes, such as
inflammatory cell infiltration and hyperemia and the
presence of a desmoplastic reaction [32].
Since true separation of the hepatic artery and portal
venous tissue time-enhancement curves is impossible using
CTP, the arterial and portal fractions of the liver perfusion
can only be estimated. Mathematical models that do so,
therefore, all have certain limitations. The direct maximum
slope method uses the temporal interval between the pre-
splenic-peak maximum slope, where hepatic artery con-
tribution is maximum (assuming portal venous contrast
inflow and hepatic venous contrast outflow are negligible)
and the post-splenic-peak maximum slope, where portal
venous contribution is maximum (assuming arterial con-
trast inflow and hepatic venous contrast outflow reached a
plateau and portal venous contribution to the hepatic vein
contrast outflow is negligible). The time at which the
maximum slope of the portal venous tissue time-enhance-
Fig. 6 Another example of liver metastasis (white boxes)
undetected with four-phase CT [unenhanced (a); arterial phase
(b); portal venous phase (c)] and detected on the CTP blood-flow
maps [arterial (d) and portal venous (e)]. Retrospectively a vague
heterogeneous lesion can be identified on the arterial and portal
venous phase images. At surgery, the lesion appeared irresectable
but suitable for RFA (f). Three days after surgery and RFA, the 80-
year-old male patient died of an autopsy-proven massive myocardial
infarction. At histology, the lesion was confirmed as a post-RFA
(needle tract and ablation zone clearly visible) colorectal liver
metastasis (g)
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ment-curve is reached often parallels a post-peak negative
slope of the arterial time-enhancement curve. Although this
phenomenon may systematically lead to some under-
estimation of the portal venous liver-tissue perfusion, this
is especially clear in regions where arterial perfusion is
very high, such as rim regions surrounding liver tumors
[20]. The increase in scan range allows us to scan entire
volumes of the liver at the cost of a lower temporal
resolution. This has several drawbacks, such as a decrease
in signal-to-noise ratio and the possible scenario of missing
an aortic or portal venous peak enhancement during the
interscan interval, which may lead to an overestimation of
the flow.However, scanning the entire liver volume solves the
problem of having no visible portal vein present within the
selected slice, which often was the case in single-level CTP.
Compared to contrast-enhanced CT, MRI and especially
SPIO-enhanced MRI seem to have a slightly superior
sensitivity and specificity whereas PET clearly has an
inferior sensitivity but superior specificity for CRLM;
furthermore PET can also detect more patients with
extrahepatic disease [33]. The lower costs and widespread
availability however may favor the use of CT over MRI
despite the radiation dose, especially if the accuracy of
detection and characterization of focal liver lesions further
improves with dynamic or at least multiphase CT.
To conclude, total-liver-volume CTP is a noninvasive,
well-tolerated, quantifiable and feasible but time-consuming
technique,which can be implemented in routine preoperative
and follow-up examinations of patientswith livermetastases.
The combination of automated and especially manual image
fusion improves the quality of blood-flow maps and enables
more reliable calculations of liver tissue perfusion, especially
in subdiaphragmatic ROIs most vulnerable to distortion
artifacts induced by differences in inspiratory volume.
Preliminary results suggest an improved detection of colo-
rectal liver metastases, although differentiation with benign
focal perfusion alterations remains difficult and needs to be
investigated in future work. Future software developments
should focus on shortening reconstruction time and making
nonlinear improved image registration possible.
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